We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 3,084

CSPI threatens litigation against Plum Organics and Gerber over allegedly deceptive trade practices
  • Shook Hardy & Bacon LLP
  • USA
  • May 15 2015

The Center for Science in the Public Interest (CSPI) has threatened to bring lawsuits against Plum Organics and Gerber Products Co. for allegedly


RWJF study: industry takes “baby steps” in curtailing food marketing to children
  • Shook Hardy & Bacon LLP
  • USA
  • May 15 2015

A study funded by the Robert Wood Johnson Foundation's Healthy Eating Research Program claims that a decrease in TV food advertisements directed to


Amarin v. FDA focuses the spotlight on the First Amendment and the FDA's regulation of off-label promotion
  • Cozen O'Connor
  • USA
  • May 11 2015

That didn't take long. Last Monday, we recommended a recent Journal of Law and the Biosciences article proposing a new model under which the FDA


Compounded drugs marketed to TRICARE beneficiaries undergoing close examination by federal investigators
  • Roetzel & Andress
  • USA
  • May 11 2015

Ongoing investigations by both the Department of Defense (DOD) and a major U.S. media organization allege that suspicious marketing and prescribing


OPDP to study the impact of comparative pricing information in DTC and professional prescription ads
  • Loeb & Loeb LLP
  • USA
  • May 7 2015

The agency will investigate how prescription drug product perceptions are impacted by the inclusion of price comparison information and supplementary


The amended PRC Advertising Law’s impact on Health-related Advertisements
  • King & Wood Mallesons
  • China
  • May 4 2015

On April 24, 2015, the PRC Advertising Law was amended for the first time since its promulgation in 1994 (the "New Advertising Law") and will take


Defamation claims brought by Texas health care providers will be subject to Anti-SLAPP Act requirements
  • Porter Hedges LLP
  • USA
  • April 30 2015

Health care providers should keep in mind that virtually any suit alleging defamation or other harm from a "communication" relating to the provision


Recent changes to the rules regulating pharmaceutical advertising
  • Baker & McKenzie
  • Kazakhstan
  • April 30 2015

Kazakhstan recently amended its legislation regulating the pharmaceutical sector. Among other things, the amendments introduced new guidelines for


Leonardo in scrubs
  • Graydon Head & Ritchey LLP
  • USA
  • April 24 2015

Visual problem-solving has an enormous role in health care and the practice of medicine, and it's rapidly changing. Technology is reshaping the ways


New active substances and global marketing authorisations
  • Taylor Wessing
  • European Union
  • April 20 2015

Data and marketing exclusivity (otherwise known as regulatory data protection) prevents the use of pre-clinical and clinical data produced for the